Cross-Disease Transcriptomics: Unique IL-17A Signaling in Psoriasis Lesions and an Autoimmune PBMC Signature

Journal of Investigative Dermatology

Volumn 136, Issue 9, 2016, Pages 1820-1830

  Swindell, William R ^a,b   Sarkar, Mrinal K ^b   Liang, Yun ^b   Xing, Xianying ^b   Gudjonsson, Johann E ^b  

^a OHIO UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 2; CALGRANULIN A; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 19; STAT1 PROTEIN; TUMOR NECROSIS FACTOR; CYTOKINE; IL17A PROTEIN, HUMAN; POLYALLYLAMINE-BENZOPHENONE-MALEIMIDOCARBOXYLATE; POLYAMINE; TRANSCRIPTOME;

ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DERMATITIS; DOWN REGULATION; GENE; GENE EXPRESSION; GENE FUNCTION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; INFLAMMATORY CELL; JUVENILE RHEUMATOID ARTHRITIS; KERATINOCYTE; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROARRAY ANALYSIS; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PSORIASIS; RNA SEQUENCE; SARCOIDOSIS; TRANSCRIPTOMICS; DNA MICROARRAY; EPIDEMIOLOGY; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; INCIDENCE; MALE; META ANALYSIS; METABOLISM; PATHOPHYSIOLOGY; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION;

CYTOKINES; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; INTERLEUKIN-17; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYAMINES; PROGNOSIS; PSORIASIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; TRANSCRIPTOME;

EID: 84992491178     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1016/j.jid.2016.04.035     Document Type: Article

References (32)

1. Arlette, J.P., Trotter, M.J., Squamous cell carcinoma in situ of the skin: history, presentation, biology and treatment. Australas J Dermatol 45 (2004), 1–9.
2. Cameron, A.L., Kirby, B., Griffiths, C.E., Circulating natural killer cells in psoriasis. Br J Dermatol 149 (2003), 160–164.
3. Choy, D.F., Hsu, D.K., Seshasayee, D., Fung, M.A., Modrusan, Z., Martin, F., et al. Comparative transcriptomic analyses of atopic dermatitis and psoriasis reveal shared neutrophilic inflammation. J Allergy Clin Immunol 130 (2012), 1335–1343.e5.
4. D'Erme, A.M., Wilsmann-Theis, D., Wagenpfeil, J., Hölzel, M., Ferring-Schmitt, S., Sternberg, S., et al. IL-36gamma (IL-1F9) is a biomarker for psoriasis skin lesions. J Invest Dermatol 135 (2015), 1025–1032.
5. Dhingra, N., Suarez-Farinas, M., Fuentes-Duculan, J., Gittler, J.K., Shemer, A., Raz, A., et al. Attenuated neutrophil axis in atopic dermatitis compared to psoriasis reflects TH17 pathway differences between these diseases. J Allergy Clin Immunol 132 (2013), 498–501.e3.
6. Griffiths, C.E., Reich, K., Lebwohl, M., van de Kerkhof, P., Paul, C., Menter, A., et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 386 (2015), 541–551.
7. Haider, A.S., Peters, S.B., Kaporis, H., Cardinale, I., Fei, J., Ott, J., et al. Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia. J Invest Dermatol 126 (2006), 869–881.
8. Inkeles, M.S., Scumpia, P.O., Swindell, W.R., Lopez, D., Teles, R.M., Graeber, T.G., et al. Comparison of molecular signatures from multiple skin diseases identifies mechanisms of immunopathogenesis. J Invest Dermatol 135 (2015), 151–159.
9. Jabbari, A., Suarez-Farinas, M., Dewell, S., Krueger, J.G., Transcriptional profiling of psoriasis using RNA-seq reveals previously unidentified differentially expressed genes. J Invest Dermatol 132 (2012), 246–249.
10. Keermann, M., Koks, S., Reimann, E., Prans, E., Abram, K., Kingo, K., Transcriptional landscape of psoriasis identifies the involvement of IL36 and IL36RN. BMC Genomics, 16, 2015, 322.
11. Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., Salzberg, S.L., TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol, 14, 2013, R36.
12. Langley, R.G., Elewski, B.E., Lebwohl, M., Reich, K., Griffiths, C.E., Papp, K., et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med 371 (2014), 326–338.
13. Law, C.W., Chen, Y., Shi, W., Smyth, G.K., voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol, 15, 2014, R29.
14. Lebwohl, M., Strober, B., Menter, A., Gordon, K., Weglowska, J., Puig, L., et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 373 (2015), 1318–1328.
15. Li, B., Tsoi, L.C., Swindell, W.R., Gudjonsson, J.E., Tejasvi, T., Johnston, A., et al. Transcriptome analysis of psoriasis in a large case-control sample: RNA-seq provides insights into disease mechanisms. J Invest Dermatol 134 (2014), 1828–1838.
16. Liu, R., Van Kaer, L., La Cava, A., Price, M., Campagnolo, D.I., Collins, M., et al. Autoreactive T cells mediate NK cell degeneration in autoimmune disease. J Immunol 176 (2006), 5247–5254.
17. Nomura, I., Gao, B., Boguniewicz, M., Darst, M.A., Travers, J.B., Leung, D.Y., Distinct patterns of gene expression in the skin lesions of atopic dermatitis and psoriasis: a gene microarray analysis. J Allergy Clin Immunol 112 (2003), 1195–1202.
18. Perera, G.K., Ainali, C., Semenova, E., Hundhausen, C., Barinaga, G., Kassen, D., et al. Integrative biology approach identifies cytokine targeting strategies for psoriasis. Sci Transl Med, 6, 2014, 223ra222.
19. Rung, J., Brazma, A., Reuse of public genome-wide gene expression data. Nat Rev Genet 14 (2013), 89–99.
20. Shi, F.D., Van Kaer, L., Reciprocal regulation between natural killer cells and autoreactive T cells. Nat Rev Immunol 6 (2006), 751–760.
21. Shi, F.D., Zhou, Q., Natural killer cells as indispensable players and therapeutic targets in autoimmunity. Autoimmunity 44 (2011), 3–10.
22. Smyth, G.K., Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol, 3, 2004, 3.
23. Swindell, W.R., Johnston, A., Voorhees, J.J., Elder, J.T., Gudjonsson, J.E., Dissecting the psoriasis transcriptome: inflammatory- and cytokine-driven gene expression in lesions from 163 patients. BMC Genomics, 14, 2013, 527.
24. Swindell, W.R., Johnston, A., Xing, X., Voorhees, J.J., Elder, J.T., Gudjonsson, J.E., Modulation of epidermal transcription circuits in psoriasis: new links between inflammation and hyperproliferation. PloS ONE, 8, 2013, e79253.
25. Swindell, W.R., Remmer, H.A., Sarkar, M.K., Xing, X., Barnes, D.H., Wolterink, L., et al. Proteogenomic analysis of psoriasis reveals discordant and concordant changes in mRNA and protein abundance. Genome Med, 7, 2015, 86.
26. Swindell, W.R., Sarkar, M.K., Stuart, P.E., Voorhees, J.J., Elder, J.T., Johnston, A., et al. Psoriasis drug development and GWAS interpretation through in silico analysis of transcription factor binding sites. Clin Transl Med, 4, 2015, 13.
27. Swindell, W.R., Stuart, P.E., Sarkar, M.K., Voorhees, J.J., Elder, J.T., Johnston, A., et al. Cellular dissection of psoriasis for transcriptome analyses and the post-GWAS era. BMC Med Genomics, 7, 2014, 27.
28. Swindell, W.R., Xing, X., Voorhees, J.J., Elder, J.T., Johnston, A., Gudjonsson, J.E., Integrative RNA-seq and microarray data analysis reveals GC content and gene length biases in the psoriasis transcriptome. Physiol Genomics 46 (2014), 533–546.
29. Tian, S., Krueger, J.G., Li, K., Jabbari, A., Brodmerkel, C., Lowes, M.A., et al. Meta-analysis derived (MAD) transcriptome of psoriasis defines the “core” pathogenesis of disease. PloS ONE, 7, 2012, e44274.
30. Tsoi, L.C., Iyer, M.K., Stuart, P.E., Swindell, W.R., Gudjonsson, J.E., Tejasvi, T., et al. Analysis of long non-coding RNAs highlights tissue-specific expression patterns and epigenetic profiles in normal and psoriatic skin. Genome Biol, 16, 2015, 24.
31. Wong, D., Kea, B., Pesich, R., Higgs, B.W., Zhu, W., Brown, P., et al. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PloS ONE, 7, 2012, e29161.
32. Yao, Y., Richman, L., Morehouse, C., de los Reyes, M., Higgs, B.W., Boutrin, A., et al. Type I interferon: potential therapeutic target for psoriasis?. PloS ONE, 3, 2008, e2737.